Arrowhead Pharmaceuticals Inc
$ 66.69
4.55%
14 Apr - close price
- Market Cap 9,338,747,000 USD
- Current Price $ 66.69
- High / Low $ 67.49 / 63.98
- Stock P/E 41.68
- Book Value 4.14
- EPS 1.60
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.14 %
- ROE 0.76 %
- 52 Week High 76.76
- 52 Week Low 10.92
About
Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.
Analyst Target Price
$81.09
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-10 | 2025-11-25 | 2025-08-07 | 2025-05-07 | 2025-02-04 | 2024-11-27 | 2024-08-08 | 2024-05-09 | 2024-02-06 | 2023-11-29 | 2023-08-07 | 2023-05-02 |
| Reported EPS | 0.22 | -0.11 | -1.26 | 2.75 | -1.39 | -1.37 | -1.38 | -1.02 | -1.24 | -1.02 | -0.96 | 0.45 |
| Estimated EPS | 0.1149 | -0.3099 | -0.86 | -0.4622 | -0.7234 | -0.922 | -0.55 | -0.16 | -0.82 | -0.6 | -0.65 | -0.64 |
| Surprise | 0.1051 | 0.1999 | -0.4 | 3.2122 | -0.6666 | -0.448 | -0.83 | -0.86 | -0.42 | -0.42 | -0.31 | 1.09 |
| Surprise Percentage | 91.4708% | 64.5047% | -46.5116% | 694.9805% | -92.1482% | -48.59% | -150.9091% | -537.5% | -51.2195% | -70% | -47.6923% | 170.3125% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.04 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARWR
2026-04-11 11:09:28
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is identified as a promising growth stock, combining strong fundamental growth metrics with a constructive technical setup. The company exhibits exceptional historical and projected revenue/EPS growth, high profitability ratios, and a strong balance sheet. Technically, ARWR shows positive trend alignment, consolidation near resistance, and high relative strength, suggesting a potential breakout, though low recent volume is a cautionary note.
2026-04-08 14:39:48
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR) with a $100 price target. This recommendation follows a strong financial quarter for Arrowhead, which reported $264.03 million in revenue and $30.81 million in net profit. While another firm issued a Hold rating, Trucchio is a highly-rated analyst covering the Healthcare sector.
2026-04-07 07:09:45
Aberdeen Group plc reduced its stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR) by 45.0% in Q4 2025, selling 234,498 shares and retaining 286,146 shares valued at $18.997 million. Despite the sell-off, other hedge funds increased their positions, and analysts maintain a "Moderate Buy" rating with a consensus price target of $81.67. Arrowhead Pharmaceuticals reported Q4 EPS of $0.22, missing expectations, but revenue beat estimates at $264.0 million.
2026-04-06 22:09:13
Arrowhead Pharmaceuticals (ARWR) stock rose 5.9% following the release of durable two-year data for its investigational drug plozasiran, showing sustained triglyceride reductions and consistent safety in patients with severe hypertriglyceridemia. This data reinforces the potential of plozasiran for severe lipid disorders and supports ongoing Phase 3 programs and regulatory plans. The article discusses how this positive data impacts Arrowhead's investment narrative, emphasizing its RNAi platform and the importance of upcoming Phase 3 readouts.
2026-04-06 07:41:08
Arrowhead Pharmaceuticals saw its stock (ARWR) rise by 5.9% following the release of durable two-year data for its investigational drug plozasiran in patients with severe and mixed hypertriglyceridemia. The data, building on earlier Phase 2b results, showed consistent safety and sustained triglyceride reductions, supporting ongoing global Phase 3 programs and regulatory plans for the RNAi platform. This positive development reinforces plozasiran's potential and strengthens the company's investment narrative ahead of crucial Phase 3 readouts and planned regulatory filings.
2026-04-06 06:40:03
Arrowhead Pharmaceuticals (NASDAQ:ARWR) has received a "Moderate Buy" consensus recommendation from brokerages, with an average 12-month price target of $81.67. This comes despite mixed quarterly results where the company missed EPS estimates but significantly beat revenue expectations. Insider selling by a director and substantial institutional investment activity have also been noted.
